Johnson & Johnson Beheer
Beheer criteriumcontroles 2/4
De CEO Johnson & Johnson is Joaquin Duato, benoemd in Jan2022, heeft een ambtstermijn van 4.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 32.76M, bestaande uit 4.9% salaris en 95.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.015% van de aandelen van het bedrijf, ter waarde $ 88.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.6 jaar en 6.1 jaar.
Belangrijke informatie
Joaquin Duato
Algemeen directeur
US$32.8m
Totale compensatie
| Percentage CEO-salaris | 4.88% |
| Dienstverband CEO | 4.5yrs |
| Eigendom CEO | 0.01% |
| Management gemiddelde ambtstermijn | 6.6yrs |
| Gemiddelde ambtstermijn bestuur | 6.1yrs |
Recente managementupdates
Recent updates
Seeking Alpha • Jul 15
Johnson & Johnson Q2: Solid (If Not Spectacular) Performance Satisfies Wall Street
Summary Johnson & Johnson delivered strong Q2 2026 results, with 6.6% annual revenue growth and robust performance across Pharma and MedTech divisions. JNJ maintains mid-to-high single digit revenue growth, a portfolio of 15+ "blockbuster" drugs, and a solid pipeline, supporting its blue-chip status. I am downgrading JNJ from Strong Buy to Buy due to valuation normalization and tempered forward share price expectations, despite continued operational strength. JNJ offers stable dividends (>2% yield), high profitability (27.5% operating margin in 2025), and remains a reliable 'buy and hold' within Big Pharma. Read the full article on Seeking Alpha
Narratiefupdate • Jul 03
JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules
For Johnson & Johnson, the analyst price target has been revised higher. The updated fair value estimate has moved from about $181.77 to $212.24 as analysts factor in refreshed revenue growth assumptions, slightly adjusted discount and margin inputs, and a higher future P/E in light of recent research pointing to ongoing new drug momentum and broadly supportive earnings expectations.Analyse-artikel • Jun 21
Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus
Johnson & Johnson (JNJ) is back in focus after recent share price weakness, with the stock down 2% over the past month and about 3% over the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Johnson & Johnson. Despite the recent share price weakness over the past week and quarter, Johnson & Johnson’s year to date share price return of 10.15% and 1 year total shareholder return of 56.28% point to momentum that has been positive overall. If this kind of move...
Narratiefupdate • Jun 19
JNJ: Future Drug Cycle And Dividend Strength Will Balance Policy And Legal Risks
Analysts have raised the Johnson & Johnson price target to $265 from $252, reflecting increased confidence in the company’s new drug momentum and product cycle, while also considering ongoing policy and partnership risks highlighted in recent research. Analyst Commentary Recent Street research around Johnson & Johnson highlights a mix of enthusiasm about the company’s new drug pipeline and product cycle, alongside fresh policy questions and selected partnership headwinds that investors should factor into expectations for execution and valuation.Narratiefupdate • Jun 04
JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns
Analysts have nudged their price targets for Johnson & Johnson higher, with recent revisions clustering in the mid to high $260s and up to $280, as they point to strong new drug momentum and product cycle strength as key drivers supporting slightly higher revenue growth expectations and a rich future P/E framework. Analyst Commentary Recent research remains broadly constructive on Johnson & Johnson, with several bullish analysts citing product cycle momentum, new drug contributions, and a supportive P/E setup.Narratiefupdate • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.Narratiefupdate • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.Narratiefupdate • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.Narratiefupdate • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.Nieuw narratief • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.Narratiefupdate • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.Narratiefupdate • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.Narratiefupdate • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
Nieuw narratief • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Jan 09
JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward
Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 28 2026 | n/a | n/a | US$21b |
| Mar 29 2026 | n/a | n/a | US$21b |
| Dec 28 2025 | US$33m | US$2m | US$27b |
| Sep 28 2025 | n/a | n/a | US$25b |
| Jun 29 2025 | n/a | n/a | US$23b |
| Mar 30 2025 | n/a | n/a | US$22b |
| Dec 29 2024 | US$24m | US$2m | US$14b |
| Sep 29 2024 | n/a | n/a | US$15b |
| Jun 30 2024 | n/a | n/a | US$16b |
| Mar 31 2024 | n/a | n/a | US$17b |
| Dec 31 2023 | US$28m | US$2m | US$13b |
| Oct 01 2023 | n/a | n/a | US$12b |
| Jul 02 2023 | n/a | n/a | US$12b |
| Apr 02 2023 | n/a | n/a | US$11b |
| Jan 01 2023 | US$13m | US$1m | US$16b |
| Oct 02 2022 | n/a | n/a | US$18b |
| Jul 03 2022 | n/a | n/a | US$17b |
| Apr 03 2022 | n/a | n/a | US$20b |
| Jan 02 2022 | US$14m | US$1m | US$18b |
| Oct 03 2021 | n/a | n/a | US$18b |
| Jul 04 2021 | n/a | n/a | US$18b |
| Apr 04 2021 | n/a | n/a | US$15b |
| Jan 03 2021 | n/a | n/a | US$15b |
| Sep 27 2020 | n/a | n/a | US$17b |
| Jun 28 2020 | n/a | n/a | US$15b |
| Mar 29 2020 | n/a | n/a | US$17b |
| Dec 29 2019 | US$13m | US$970k | US$15b |
Compensatie versus markt: De totale vergoeding ($USD 32.76M ) Joaquin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.57M ).
Compensatie versus inkomsten: De beloning van Joaquin is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Joaquin Duato (63 yo)
4.5yrs
Tenure
US$32,758,111
Compensatie
Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 4.5yrs | US$32.76m | 0.015% $ 88.0m | |
| Executive VP & CFO | 8yrs | US$14.41m | 0.0035% $ 21.0m | |
| Executive VP & Worldwide Chairman of Innovative Medicine | 14.5yrs | US$14.03m | 0.0081% $ 48.0m | |
| Executive Vice President of Innovative Medicine and R&D | 3.3yrs | US$12.21m | 0.0010% $ 6.1m | |
| Executive VP & Worldwide Chairman of MedTech | 2.8yrs | US$9.34m | 0.0011% $ 6.5m | |
| Controller & Chief Accounting Officer | 6.6yrs | geen gegevens | 0.0010% $ 6.1m | |
| Executive VP & Chief Information Officer | 6.7yrs | geen gegevens | 0.0011% $ 6.4m | |
| Chief Compliance Officer | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief Legal Officer | 3.8yrs | geen gegevens | 0.00098% $ 5.8m | |
| Executive VP & Chief Human Resources Officer | no data | geen gegevens | 0.00082% $ 4.9m | |
| Group Chairman of MD&D Business - EMEA | no data | geen gegevens | geen gegevens | |
| Executive VP and Chief Technical Operations & Risk Officer | 8yrs | geen gegevens | 0.0048% $ 28.3m |
6.6yrs
Gemiddelde duur
59.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van JNJ is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 4.5yrs | US$32.76m | 0.015% $ 88.0m | |
| Director | less than a year | US$59.13k | 0.000080% $ 475.7k | |
| Independent Director | 6.6yrs | US$367.55k | 0.00021% $ 1.2m | |
| Lead Independent Director | 7.3yrs | US$413.00k | 0.00012% $ 713.6k | |
| Independent Director | 3.4yrs | US$344.00k | 0.000010% $ 59.5k | |
| Independent Director | 12.8yrs | US$330.00k | 0% $ 0 | |
| Independent Director | 11.1yrs | US$375.00k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$370.00k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$347.16k | 0.000010% $ 59.5k | |
| Independent Director | 6.6yrs | US$355.00k | 0.000040% $ 237.9k | |
| Director | 1yr | US$62.50k | geen gegevens | |
| Independent Director | 5.6yrs | US$350.00k | 0% $ 0 |
6.1yrs
Gemiddelde duur
63.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van JNJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/16 03:49 |
| Aandelenkoers aan het einde van de dag | 2026/07/16 00:00 |
| Inkomsten | 2026/06/28 |
| Jaarlijkse inkomsten | 2025/12/28 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Johnson & Johnson wordt gevolgd door 53 analisten. 22 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |